業績

HOME > 業績 > その他
  • その他 STRIDE sustained an overall survival benefit with safety profiles in unresectable hepatocellular carcinoma at 5-year follow-up
    Kanda T, Sasaki-Tanaka R, Kamimura H, Hayashi K, Kamimura K, Terai S.
    Hepatobiliary Surg Nutr. 2026 Feb 1;15(1):17. doi: 10.21037/hbsn-2025-658. Epub 2026 Jan 20.
  • その他 Pre-eradication fecal Helicobacter pylori antigen levels as a predictive marker for skin eruption during eradication therapy
    Kawai T, Hayashi R, Hasegawa A, Sato H, Takahashi K, Kohisa J, Waguri N, Yokoyama J, Honma T, Miyazawa T, Terai S, Abe R.
    J Invest Dermatol. 2026 Jan 23:S0022-202X(26)00031-X. doi: 10.1016/j.jid.2026.01.010.
  • その他 Is higher body mass index correlated with worse clinical outcomes in acute liver failure?
    Kanda T, Sasaki-Tanaka R, Kamimura H, Terai S.
    World J Clin Cases. 2025 Nov 16;13(32):113514. doi: 10.12998/wjcc.v13.i32.113514.
  • その他 International Society of Cell and Gene Therapy 2025 exosomes signature series: a thematic synthesis for advancing mesenchymal stromal cell-derived extracellular vesicle therapies
    Tertel T, Giebel B, Lee RH, Muraca M, Ortiz LA, Parolini O, Perruche S, Robbins PD, Rohde E, Strader SR, Terai S, Toh WS, Yarani R, Weiss DJ, Wiest EF, Lim SK.
    Cytotherapy. 2025 Nov 28;28(3):102016. doi: 10.1016/j.jcyt.2025.102016.
  • その他 Importance of understanding a diagnostic-treatment algorithm for primary hyperparathyroidism-induced acute pancreatitis during pregnancy
    Kamimura K, Terai S.
    World J Gastroenterol. 2025 May 14;31(18):105866. doi: 10.3748/wjg.v31.i18.105866.
  • その他 Cholestasis in hepatitis E virus infection
    Kanda T, Sasaki-Tanaka R, Yokoo T, Hayashi K, Kamimura H, Tsuchiya A, Terai S.
    World J Hepatol. 2025 Apr 27;17(4):99899. doi: 10.4254/wjh.v17.i4.99899.
  • その他 Combination therapies with immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma with major vascular invasion
    Kanda T, Sasaki-Tanaka R, Terai S.
    Hepatol Int. 2025 Feb 8. doi: 10.1007/s12072-025-10784-9.
  • その他 Deriving Human Intestinal Organoids with Functional Tissue-Resident Macrophages All From Pluripotent Stem Cells.
    Tominaga K, et al.
    Cell Mol Gastroenterol Hepatol. 2025;19(4):101444.
  • その他 Eicosatetraynoic Acid Regulates Profibrotic Pathways in an Induced Pluripotent Stem Cell-Derived Macrophage-Human Intestinal Organoid Model of Crohn’s Disease.
    Jurickova I, Tominaga K, et al.
    J Crohns Colitis. 2025;19(2):jjae139.
  • その他 B型肝炎ウイルスについて
    上村 博輝
    2024年度肝がん撲滅運動 市民公開講座オンデマンド